(Q44452832)

3 December 2017

title

A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia (English)

1 reference

3 December 2017

0 references

2

Karu Jayathilake

1 reference

3 December 2017

Tomiki Sumiyoshi

1

1 reference

3 December 2017

Herbert Y Meltzer

series ordinal

3

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

3 December 2017

published in

Schizophrenia Research

1 reference

3 December 2017

volume

62

1 reference

3 December 2017

issue

1-2

1 reference

3 December 2017

page(s)

65-72

1 reference

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

A comprehensive psychopathological rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

The use of atypical antipsychotics in the management of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Nuclear medicine in neurology and psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Melperone in the treatment of neuroleptic-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900351-1

7 January 2021

10.1016/S0920-9964(02)00351-1

Identifiers

DOI

1 reference

3 December 2017

1 reference